Literature DB >> 18178401

Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients.

Sorin J Brener1, John M Galla, Roosevelt Bryant, Joseph F Sabik, Stephen G Ellis.   

Abstract

Coronary artery bypass grafting (CABG) has been the recommended treatment for patients with significant left main coronary artery (LMCA) stenosis. Advances in stent technology have invigorated investigations into the suitability of a percutaneous approach for these patients. Favorable short-term results from nonrandomized comparisons were previously reported. Patients (n = 97) who underwent percutaneous coronary intervention for severe (>70%) LMCA stenosis were matched in a 1:2 ratio with a cohort that underwent surgical revascularization (n = 190). The groups were similar for age, gender, European System for Cardiac Operative Risk Evaluation, left ventricular ejection fraction, history of myocardial infarction, and presence of renal disease. Kaplan-Meier estimates of 3-year mortality were similar for the PCI and CABG groups at 80% (95% confidence interval [CI] 68 to 88) versus 85% (95% CI 79 to 89, p = 0.14), respectively. Propensity score-adjusted 3-year mortality did not differ between groups (p = 0.22). Multivariable modeling identified only higher European System for Cardiac Operative Risk Evaluation (hazard rate 1.33, 95% CI 1.16 to 1.54, p <0.001) and the presence of diabetes mellitus (hazard rate 1.96, 95% CI 1.24 to 3.09, p = 0.004) as independent risks of mortality at 3 years. In conclusion, patients who underwent percutaneous revascularization of severe LMCA stenosis appeared to have 3-year survival equivalent to those who underwent CABG. Diabetes mellitus and advanced co-morbidity were the principal determinants of survival. These findings support the need for randomized trials with adequate follow-up to compare the 2 approaches.

Entities:  

Mesh:

Year:  2007        PMID: 18178401     DOI: 10.1016/j.amjcard.2007.08.054

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  14 in total

1.  Bypass surgery versus percutaneous coronary intervention for the treatment of unprotected left main disease. A meta-analysis of randomized controlled trials.

Authors:  S Desch; E Boudriot; A Rastan; P E Buszman; A Bochenek; F W Mohr; G Schuler; H Thiele
Journal:  Herz       Date:  2012-03-11       Impact factor: 1.443

2.  2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Developed in collaboration with the American College of Surgeons, American Society of Anesthesiologists, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Anesthesiologists, and Society of Vascular Medicine Endorsed by the Society of Hospital Medicine.

Authors:  Lee A Fleisher; Kirsten E Fleischmann; Andrew D Auerbach; Susan A Barnason; Joshua A Beckman; Biykem Bozkurt; Victor G Davila-Roman; Marie D Gerhard-Herman; Thomas A Holly; Garvan C Kane; Joseph E Marine; M Timothy Nelson; Crystal C Spencer; Annemarie Thompson; Henry H Ting; Barry F Uretsky; Duminda N Wijeysundera
Journal:  J Nucl Cardiol       Date:  2015-02       Impact factor: 5.952

3.  Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention for Unprotected Left Main Disease - A Review.

Authors:  Edward McNulty
Journal:  Interv Cardiol       Date:  2013-03

4.  Early and long-term outcomes of coronary artery bypass grafting and percutaneous coronary intervention in patients with left main disease: single-center results of multidisciplinary decision making.

Authors:  Toshihiro Fukui; Minoru Tabata; Tetsuya Tobaru; Ryuta Asano; Shuichiro Takanashi; Tetsuya Sumiyoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-12-08

5.  Drug-eluting versus bare-metal stents in unprotected left main coronary artery stenosis a meta-analysis.

Authors:  Sanjay B Pandya; Young-Hak Kim; Sheridan N Meyers; Charles J Davidson; James D Flaherty; Duk-Woo Park; Anuj Mediratta; Karen Pieper; Eric Reyes; Robert O Bonow; Seung-Jung Park; Nirat Beohar
Journal:  JACC Cardiovasc Interv       Date:  2010-06       Impact factor: 11.195

6.  Excimer laser debulking for percutaneous coronary intervention in left main coronary artery disease.

Authors:  On Topaz; Pritam R Polkampally; Pramod K Mohanty; Maged Rizk; Julie Bangs; Nelson L Bernardo
Journal:  Lasers Med Sci       Date:  2009-02-24       Impact factor: 3.161

7.  Impact of routine angiographic follow-up after percutaneous coronary drug-eluting stenting for unprotected left main disease: the Turin Registry.

Authors:  Giuseppe G L Biondi-Zoccai; Elena Giraudi; Claudio Moretti; Filippo Sciuto; Pierluigi Omedè; Dario Sillano; Paolo Garrone; Gian Paolo Trevi; Imad Sheiban
Journal:  Clin Res Cardiol       Date:  2010-01-03       Impact factor: 5.460

8.  Different treatment options in chronic coronary artery disease: when is it the time for medical treatment, percutaneous coronary intervention or aortocoronary bypass surgery?

Authors:  Martin Russ; Karl Werdan; Jochen Cremer; Arno Krian; Thomas Meinertz; Hans-Reinhard Zerkowski
Journal:  Dtsch Arztebl Int       Date:  2009-04-10       Impact factor: 5.594

9.  Unprotected left main revascularization in patients with acute coronary syndromes.

Authors:  Gilles Montalescot; David Brieger; Kim A Eagle; Frederick A Anderson; Gordon FitzGerald; Michael S Lee; Ph Gabriel Steg; Alvaro Avezum; Shaun G Goodman; Joel M Gore
Journal:  Eur Heart J       Date:  2009-08-30       Impact factor: 29.983

10.  Comparison of bypass surgery with drug-eluting stents in diabetic patients with left main coronary stenosis.

Authors:  Xiaoxiao Zhao; Yujie Zhou; Hui Song; Like Guan; Guanbin Zheng; Zhehu Jin; Dongmei Shi; Yuzi Li; Yonghe Guo; Guo-Ping Shi; Xian Wu Cheng
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.